NCT06875063View on ClinicalTrials.gov

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 15, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Non-hodgkin Lymphoma,B CellRelapsed Non-Hodgkin LymphomaRefractory LymphomaChimeric Antigen Receptor T-cell
Interventions
DRUG

GB5005 CART

Included patients will receive GB5005 chimeric antigen receptor T-cell injection: A sterile syringe will be used to draw the assigned dose volume (calculated based on the patient's weight and converted to volume). The cells will be slowly infused intravenously at a rate of about 10 mL/min.

Trial Locations (1)

361000

RECRUITING

Bing Xu, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER